<DOC>
	<DOC>NCT02785250</DOC>
	<brief_summary>Immunotherapeutic survivin vaccine DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.</brief_summary>
	<brief_title>Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Key Histologically confirmed stage IIcIV epithelial ovarian, fallopian tube or peritoneal cancer Platinumresistant or sensitive after completing firstline treatment (debulking surgery and adjuvant or neoadjuvant treatment with standard of care treatment such as carboplatin and paclitaxel) Complete or partial response or stable disease by radiological imaging to most recent standard of care chemotherapy treatment Evidence of progressive disease with rising CA125 and/or radiologic progression Must have measurable disease, a successful pretreatment tumor biopsy, and be willing to undergo tumor biopsy during treatment Ambulatory with an ECOG 01 Life expectancy â‰¥ 6 months Meet protocolspecified lab requirements Key Eligible for otherwise curative treatment or undergoing concurrent therapy Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g. antiCTLA4, antiPD1, antiPDL1, or any other antibody or drug specifically targeting T cell costimulation) or an IDO inhibitor Concurrent second malignancy other than nonmelanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer Clinical ascites or metastatic pleural fluid Malignant bowel obstruction History of autoimmune disease requiring treatment within the last two years (except vitiligo or diabetes) Recent history of thyroiditis Presence of a serious acute infection or chronic infection Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases) GI condition that might limit absorption of oral agents Other serious intercurrent chronic or acute illness Ongoing treatment with steroid therapy or other immunosuppressive Receipt of monoamine oxidase inhibitors (MAOIs) or UGT1A9 inhibitors Acute or chronic skin and/or microvascular disorders Edema or lymphedema in the lower limbs &gt; grade 1</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>IDO1 inhibitor</keyword>
	<keyword>ovarian</keyword>
	<keyword>fallopian tube</keyword>
	<keyword>peritoneal</keyword>
	<keyword>cancer</keyword>
	<keyword>recurrent</keyword>
	<keyword>tumor</keyword>
	<keyword>measurable</keyword>
</DOC>